New drug candidate from Vivolux starves cancer cells – clinical study due to begin shortly

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Communications. Researchers at Vivolux have discovered a novel cancer drug target. The drug candidate kills sleeping cell populations in regions of solid tumors that are less oxygenized – areas that cannot be reached by conventional cancer therapeutics.In solid tumors, there are areas with poor vascular supply where cancer cells divide more slowly due to a lack of oxygen and nutrients. The